Daré Bioscience Inc. (DARE)
Daré Bioscience Inc. (DARE) Stock Price, Analysis & Data
| Bid | 1.03 |
| Market Cap | 20.52M |
| Revenue (ttm) | 1.16M |
| Net Income (ttm) | -12.02M |
| Beta | 1.05 |
| EPS (ttm) | -0.87 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.69 |
| P/B (ttm) | 27.40 |
| P/S (ttm) | 17.73 |
| Earnings Date | Nov 12, 2026 |
| Ask | 1.81 |
| Volume | 1,152,539 |
| Avg. Volume (20D) | 261,633 |
| Open | 1.43 |
| Previous Close | 1.44 |
| Day's Range | 1.31 - 1.46 |
| 52-Week Range | 1.13 - 3.78 |
| Analyst | n/a |
| Price Target | 9 (556.93%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DARE
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the femal...
Financial Performance
In 2025, Daré Bioscience's revenue was 1.03M, an increase of 10,429.36% compared to the previous year's 9.78K. Earnings were -13.4M, an increase of 230.55%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for DARE stock is "null". The 12-month stock price forecast is 9, which is upside of 556.93% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
